Know Cancer

or
forgot password

Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy


N/A
18 Years
N/A
Not Enrolling
Female
Breast Cancer, Estrogen Receptor, Her-2, Pgr

Thank you

Trial Information

Identifying Genomic Predictors of Recurrence After Adjuvant Chemotherapy


OBJECTIVES:

- Assess the prognostic utility of the Oncotype DX™ 21 gene profile for risk of relapse
in women with node positive or high-risk node negative breast cancer.

- Identify individual genes whose RNA expression is associated with an increased risk of
relapse in these patients.

- Perform an exploratory analysis of individual genes whose RNA expression is associated
with an increased risk of relapse differentially in patients previously treated with
docetaxel.

OUTLINE: This is a multicenter study.

Tissue samples are examined for association of RNA expression and clinical factors (e.g.,
tumor size, nodal status, hormone receptor status, age, menopause status), as well as
estrogen receptor, progesterone receptor, and HER-2/neu expression by immunohistochemistry
and other studies.

PROJECTED ACCRUAL: A total of 900 patients will be accrued for this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Diagnosis of breast cancer

- Node positive OR high-risk node negative disease

- Tumor > 1.0 cm in diameter

- No locally advanced, inflammatory, or metastatic breast cancer

- Previously treated with 4 courses of anthracycline-containing chemotherapy (i.e.,
doxorubicin and docetaxel OR doxorubicin and cyclophosphamide)

- Enrolled on clinical trial ECOG-E2197

- Adequate tumor material available in ECOG Pathology Coordination Center

- Previously consented to future cancer-related research

- Hormone receptor status known

PATIENT CHARACTERISTICS:

- Female

- Menopausal status not specified

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Distant, local/regional, and ipsilateral breast relapse

Safety Issue:

No

Principal Investigator

Joseph A. Sparano, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Albert Einstein College of Medicine of Yeshiva University

Authority:

United States: Federal Government

Study ID:

CDR0000456426

NCT ID:

NCT00897299

Start Date:

Completion Date:

Related Keywords:

  • Breast Cancer
  • Estrogen Receptor
  • Her-2
  • Pgr
  • estrogen receptor
  • HER-2
  • PgR
  • stage II breast cancer
  • stage IIIA breast cancer
  • stage IIIB breast cancer
  • Breast Neoplasms
  • Recurrence

Name

Location